Join Us

Evista for Osteoporosis

Save as Favorite
Sign in to receive recommendations (Learn more)

Leer esta página en español

Evista (chemical name: raloxifene) is a selective estrogen receptor modulator (SERM) approved by the FDA to treat and prevent osteoporosis in postmenopausal women.

Evista also is approved to reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women diagnosed with osteoporosis, as well as postmenopausal women who don’t have osteoporosis but who are at higher-than-average risk for breast cancer.

Evista is a pill taken by mouth once a day.

Learn more about Evista.


Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations



Beta How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Supportpeopleyellow banner mini
Back to Top